FDLI TOP CASES 2024/2025 by Steven A. Johnson
https://fdacounsels.com/wp-content/uploads/2024/05/FDLI-Top-Cases-in-Food-and-Drug-Law-2024-pdf-232×300.jpg
Uncategorized
FDLI Top Cases 2025 – Authorship of Article – Steven A. Johnson – FDACOUNSELS.com
FDLI TOP CASES 2025 by STEVEN A. JOHNSON
FDA Reduction in Force Actions April 1, 2025 -Significant damage to Agency, Industry and Consumer
As a former Associate Chief Counsel for FDA it was stunning to see the RIFs carried out today were arbitrary and in complete disregard for the wealth of scientific knowledge that will be forever lost. The way in which employees were dismissed was insulting as there badges inactived and then public servants corralled into a … Read more
FDLI Enforcement and LItigation Conference
https://www.fdli.org/2024/12/2024-enforcement-litigation-and-compliance-conference/
Steven A. Johnson, JD authors article in FDLI Top Cases in 2023/2024
This published article was shared with permission of FDLI. United States v. Stoll Steven A. Johnson* Why It Made the List In what is becoming more common, the U.S. Food and Drug Administration (FDA) successfully brought a criminal prosecution through the Department of Justice (DOJ) against a lower-level company individual instead of a responsible company … Read more
FDLI Top Cases 2023/2024 – Steven A. Johnson, JD
United States v. Stoll – Food and Drug Law Institute (FDLI)
FDLI Top Cases for 2023 Update by Steven A. Johnson, JD
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. FDLI Publication May 2024-Top Cases in 2023 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Successful Use of Inter Partes Review to Cancel Claims Asserted in Parallel Litigation
In a trio of March 6, 2014 inter partes review (IPR) decisions, the Patent Trial and Appeal Board (PTAB) canceled patent claims related to next generation DNA sequencing technology, after Illumina, Inc. countered Columbia University’s patent infringement suit by successfully petitioning for IPR of claims in three of five of Columbia’s patents-in-suit. The decisions illustrate … Read more
Court Offers Insights On When the 271(e)(1) Safe Harbor Applies to the Use of Patented
In a trio of March 6, 2014 inter partes review (IPR) decisions, the Patent Trial and Appeal Board (PTAB) canceled patent claims related to next generation DNA sequencing technology, after Illumina, Inc. countered Columbia University’s patent infringement suit by successfully petitioning for IPR of claims in three of five of Columbia’s patents-in-suit. The decisions illustrate … Read more
Challenges of bringing mHealth products to the market are highlighted in Duane
In a trio of March 6, 2014 inter partes review (IPR) decisions, the Patent Trial and Appeal Board (PTAB) canceled patent claims related to next generation DNA sequencing technology, after Illumina, Inc. countered Columbia University’s patent infringement suit by successfully petitioning for IPR of claims in three of five of Columbia’s patents-in-suit. The decisions illustrate … Read more